Any current/future new fundraising through debt or equity?

As of Q2 FY'25, Indegene has fully repaid its outstanding debt in the last week of June 2024 using IPO proceeds, resulting in zero interest charge on debt servicing for the quarter. The company currently holds a strong cash position of approximately INR 1,467 crore (cash and cash equivalents). Indegene continues to actively scout for M&A opportunities and maintains a healthy pipeline of potential acquisitions. There is no specific mention of planned or ongoing new fundraising through debt or equity in the current report. Overall, the company appears focused on using existing cash reserves and

Any current/future capex/capital investment/strategic investment?

Indegene continues to actively scout for M&A opportunities and has a healthy pipeline of potential acquisitions to expand or round off capabilities for integrated solutions. (Page 5) The company is deploying resources to increase the number of million-dollar customers and grow existing accounts toward larger revenue buckets such as $50 million plus clients. (Page 8) There is a focus on operating model optimization and centralization to handle upcoming new drug launches efficiently, which may imply strategic investments in operational infrastructure. (Page 13) No explicit mention of large, spec

Future growth expectations in sales/revenue/volumes?

Indegene expects modest industry growth in 2024, setting the stage for recovery after a lull. Top 35 pharma companies are forecasted to grow at a CAGR of 5%-8% from 2025 to 2028, driven by increased drug launches. Indegene is well-positioned to capitalize on growing outsourced spending and digital adoption to enhance physician and patient engagement. Company revenues grew 8% YoY and 1.5% sequentially in Q2 FY25, with core enterprise segments (85% of revenue) up 3.6% sequentially. Growth momentum expected to improve as top accounts stabilize and budgets for new product launches come in

Future growth expectations in earnings/operating earnings/profits/EPS?

Indegene aims to operate at around 20% EBITDA margin, with Q2 FY25 recording 18.4%, impacted by a 2.2% wage hike; productivity enhancements should support margin improvement towards 20% full-year and beyond in medium term (2-3 years). Revenue growth driven by enterprise commercial and medical segments, constituting 85% of revenue, with sequential growth of 3.6%; growth expected to improve as restructuring headwinds stabilize in certain large accounts. Medium-term revenue growth expected to be mid- to late-teens percentage range driven by increased outsourcing budgets, more product launches

IndegeneQ2 FY25Healthcare Services

Indegene Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹594P/E: 35.2Market Cap: ₹14.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 4

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

Indegene expects modest industry growth in 2024, setting the stage for recovery after a lull.
Top 35 pharma companies are forecasted to grow at a CAGR of 5%-8% from 2025 to 2028, driven by increased drug launches.
Indegene is well-positioned to capitalize on growing outsourced spending and digital adoption to enhance physician and patient engagement.
Company revenues grew 8% YoY and 1.5% sequentially in Q2 FY25, with core enterprise segments (85% of revenue) up 3.6% sequentially.
Growth momentum expected to improve as top accounts stabilize and budgets for new product launches come in during calendar year 2025.
Customer base expansion beyond top 20 life sciences companies is accelerating, especially in enterprise segments.
Pipeline healthy for omni-channel and consulting segments, with new projects expected to ramp up.
Medium-to-long-term goal includes mid- to late-teens percentage revenue growth, leveraging current market trends and expanding client engagements.

Margin guidance

Category 2

Indegene aims to operate at around 20% EBITDA margin, with Q2 FY25 recording 18.4%, impacted by a 2.2% wage hike; productivity enhancements should support margin improvement towards 20% full-year and beyond in medium term (2-3 years).
Revenue growth driven by enterprise commercial and medical segments, constituting 85% of revenue, with sequential growth of 3.6%; growth expected to improve as restructuring headwinds stabilize in certain large accounts.
Medium-term revenue growth expected to be mid- to late-teens percentage range driven by increased outsourcing budgets, more product launches, and expanding client footprint beyond top 20 pharma companies.
Top 35 pharma companies projected to grow at 5-8% CAGR (2025-2028), supporting outsourcing demand.
EBITDA margins adjusted to exclude interest income, targeting 20-21% EBITDA excluding interest income for FY25.
New customer acquisitions and tuck-in M&A opportunities expected to enhance growth and profitability.
PAT margin improved to 13.4% with zero interest charges post-debt repayment; Return on Equity stable in early 20s.

See what Indegene management said on margin guidance — free account, 30 seconds.

Fundraise plans

As of Q2 FY'25, Indegene has fully repaid its outstanding debt in the last week of June 2024 using IPO proceeds, resulting in zero interest charge on debt servicing for the quarter.
The company currently holds a strong cash position of approximately INR 1,467 crore (cash and cash equivalents).
Indegene continues to actively scout for M&A opportunities and maintains a healthy pipeline of potential acquisitions.
There is no specific mention of planned or ongoing new fundraising through debt or equity in the current report.
Overall, the company appears focused on using existing cash reserves and IPO proceeds to support growth and acquisitions, with no immediate need for additional fundraising indicated.

Order book

Yes

The transcript from the provided document does not explicitly mention the current or expected order book or pending orders for Indegene Limited. However, some related insights can be inferred: - The company has a healthy pipeline, especially in omni-channel and consulting segments, despite some project ramp-downs causing short-term revenue impact. - Multiple clients are preparing for increased launches in 2025 and beyond, indicating expected growth in order intake. - Positive momentum is seen from top accounts and expansion discussions with key customers are ongoing. - Growth is driven by both big pharma and mid-size pharma customers, with an increasing number of clients engaging in new models. - Indegene is actively scouting for M&A opportunities to expand capabilities and client engagements. - The company is well-positioned for the upcoming wave of drug launches which should translate into increased outsourced spending and orders. No exact figures for order book or pending orders are provided.

See what Indegene management said on order book — free account, 30 seconds.

Capex plans

Yes

Indegene continues to actively scout for M&A opportunities and has a healthy pipeline of potential acquisitions to expand or round off capabilities for integrated solutions. (Page 5)
The company is deploying resources to increase the number of million-dollar customers and grow existing accounts toward larger revenue buckets such as $50 million plus clients. (Page 8)
There is a focus on operating model optimization and centralization to handle upcoming new drug launches efficiently, which may imply strategic investments in operational infrastructure. (Page 13)
No explicit mention of large, specific capital expenditure projects, but ongoing investments in capabilities through tuck-in acquisitions and client expansion initiatives are highlighted as part of growth strategy. (Pages 8, 13)

Track Indegene — get its next earnings analysis in your feed

How does Indegene rank vs peers in Healthcare Services?

Pro feature

ThisIndegene

Rev 4Mar 2

See where Indegene sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Indegene rank in Healthcare Services?

Compare Indegene against every Healthcare Services company (Q2 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Indegene's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →